Theranostics of Neuroendocrine Tumors
Authors:
Open Access
- 1 May 2017
- journal article
- review article
- Published by S. Karger AG in Visceral Medicine
- Vol. 33 (5) , 358-366
Abstract
Somatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life.Keywords
This publication has 67 references indexed in Scilit:
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine NeoplasmsSeminars in Nuclear Medicine, 2012
- THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka ExperienceTheranostics, 2012
- Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)European Journal of Nuclear Medicine and Molecular Imaging, 2011
- Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?European Journal of Nuclear Medicine and Molecular Imaging, 2011
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideJournal of Clinical Oncology, 2010
- Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical TrialClinical Cancer Research, 2007